Avita Medical Inc traded at 1.11 this Friday March 27th, decreasing 0.01 or 0.90 percent since the previous trading session. Looking back, over the last four weeks, Avita Medical lost 19.05 percent. Over the last 12 months, its price fell by 61.50 percent. Looking ahead, we forecast Avita Medical Inc to be priced at 1.09 by the end of this quarter and at 0.99 in one year, according to Trading Economics global macro models projections and analysts expectations.
AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.